Newly minted AGC Biologics announces plans to expand manufacturing footprint

A bar chart showing positive business growth
AGC Biologics, a CDMO recently formed out of the integration of Asahi Glass Company Bioscience, Biomeva and CMC Biologics, plans to expand its headquarters in Bothell, Washington. (Getty/NicoElNino)

AGC Biologics, a CDMO recently formed out of the integration of Asahi Glass Company Bioscience, Biomeva and CMC Biologics, said it will expand its headquarters in Bothell, Washington.

The new 150,000-square-foot building complex will become part of the company’s current facility and will contain process development labs, corporate offices and room to expand AGC’s manufacturing capacity, the company said.

The addition is part of the company’s plans to expand its presence in the U.S. and will also include a R&D center for the development of new manufacturing technologies for faster development of therapeutic proteins.

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

The company didn’t disclose the projected cost of the project.

“We continue to demonstrate our dedication to sustained growth in order to support our customers’ increasing demand for both mammalian and microbial development and manufacturing services,” Gustavo Mahler, AGC’s president and CEO, said in a statement. “These new state-of-the-art facilities will enable us to meaningfully advance and further integrate the development, manufacturing, and commercial functions within our dynamic global headquarters, as well as provide additional footprint for further manufacturing expansion.”

AGC, which was formed and rebranded earlier this year, is focused on services for the scale-up and manufacturing of protein-based therapeutics.

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.